NV-CoV-1-R / NanoViricides - LARVOL DELTA

These are the treatments that President Trump is taking as he battles COVID-19 - "Dr. Prashant Malhotra...says the next week will be crucial for the president's health. He says the antiviral medication has been shown to help patients fight COVID-19 if it's administered early in the infection. The president's doctors say he's receiving a five-day course of the drug....Malhotra says there's not much data showing those over-the-counter drugs are effective against COVID-19."

Media quote • Novel Coronavirus Disease

NanoViricides: One Step at a Time (Yahoo Finance) - "...NanoViricides has gone ahead and engaged Calvert Labs, a contract research organization, for the purpose of performing the Safety Pharmacology studies on NV-CoV-1. The management intends to perform some core safety pharmacology studies to ensure the safety of the drug candidates at Calvert Labs before going ahead with the IND application. It also intends to seek pre-IND guidance from the U.S. FDA as per its press release to ensure the smooth flow of the process and minimize the risk of failure of the application."

Preclinical • Infectious Disease • Novel Coronavirus Disease

NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 (BioSpace) - "NanoViricides, Inc....today announced that it has nominated a clinical drug candidate for the treatment of COVID-19....The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1....We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic."

New molecule • Infectious Disease • Novel Coronavirus Disease

NanoViricides, Inc. Raises $11.5 Million Through Public Offering After Positive Test Results For COVID-19 Drug (Yahoo Finance) - "NanoViricides, Inc....has also been working on the development of a drug to treat the SARS-CoV-2 virus since the beginning of 2020 and has shown visible progress with positive results in the animal model....The Company would require BSL-3 or BSL-4 labs for carrying out similar studies using the actual SARS-CoV-2 strain for which the management is on the lookout for potential collaborations.....Company's management plans to conduct studies to carry out clinical candidate selection and possibly request a pre-IND meeting with the FDA for regulatory guidance. The management looks to engage in strong collaborations in the future and can also expect cash flows expected through licensing..."

FDA event • Licensing / partnership • Infectious Disease • Novel Coronavirus Disease